Proteins and peptides: The need to improve them as promising therapeutics for ulcerative colitis

References

• Al-Hilal AT, Alam F, Byun Y 2013. Oral drug delivery systems using chemical conjugates or physical complexes. Adv Drug Deliv Rev. 65:847.
   Web of Science ®Google Scholar
• Allemann E, Leroux JC, Gurny R 1998. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev. 34:172.
   Web of Science ®Google Scholar
• Allemann E, Leroux JC, Gurny R 1998. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev. 34:171–189.
   PubMed Web of Science ®Google Scholar
• Allen A, Garner A 1980. Mucus and bicarbonate secretion in the stomach and their possible role in mucosal protection. Gut. 21:249–262.
   PubMed Web of Science ®Google Scholar
• Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ 1989. Potent and prolonged acting cyclic lactam analogues of alphamelanotropin: design based on molecular dynamics. J Med Chem. 32:2555–2561.
   PubMed Web of Science ®Google Scholar
• Ambrosini R, Barchiesi A, Mizio VD, Terlizzi MD, Leo L, Filippone A, et al 2007. Inflammatory chronic disease of the colon: How to image. Eur J Radiol. 61:442.
   PubMed Web of Science ®Google Scholar
• Antosova Z, Mackova M, Kral V, Macek T 2014. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol. 27:628.
   Web of Science ®Google Scholar
• Bai JPF, Amidon GL 1992. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res. 9:969–978.
   PubMed Web of Science ®Google Scholar
• Bakhru SH, Furtado S, Morello AP, Mathiowitz E 2013. Oral delivery of proteins by biodegradable nanoparticles. Adv Drug Deliv Rev. 65:812.
   Web of Science ®Google Scholar
• Barthe L, Woodley J, Houin G 1999. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol. 13:154–168.
   PubMed Web of Science ®Google Scholar
• Bitton A 2001. Medical management of ulcerative proctitis, proctosigmoiditis, and leftsided colitis. Semin Gastrointest Dis. 12:263–274.
   PubMedGoogle Scholar
• Bokemeyer B, Hommes D, Gill I, Broberg P, Dignass A 2012. Mesalazine in left-sided ulcerative colitis: Efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J Crohn's Colitis. 6:476–482.
   Google Scholar
• Bolge SC, Waters H, Piech CT 2010. Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: results of a national internet-based survey. Clin Ther. 32:238.
   PubMed Web of Science ®Google Scholar
• Burton PS, Conradi RA, Hilgers AR 1991. (B) Mechanisms of peptide and protein absorption (2) transcellular mechanism of peptide and protein absorption: passive aspects. Adv Drug Deliv Rev. 7:365–385.
   Web of Science ®Google Scholar
• Burton PS, Conradi RA, Ho NF, Hilgers AR, Borchardt RT 1996. How structural features influence the biomembrane permeability of peptides. J Pharm Sci. 85:1336–1340.
   PubMed Web of Science ®Google Scholar
• Bysell H, Mansson R, Hansson P, Malmsten M 2011. Microgels and microcapsules in peptide and protein drug delivery. Adv Drug Deliv Rev. 63:1172–1185.
   PubMed Web of Science ®Google Scholar
• Calceti P, Salmaso S, Walker G, Schnürch AB 2004. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur J Pharm Sci. 22:315–323.
   PubMed Web of Science ®Google Scholar
• Carbonnel F, Jantchou P, Monnet E, Cosnes J 2009. Environmental risk factors in Crohn's disease and ulcerative colitis: an update. Gastroenterol Clin Biol. 33:S145–157.
   PubMedGoogle Scholar
• Carino GP, Jacob JS, Mathiowitz E 2000. Nanosphere based oral insulin delivery. J Control Release. 65:261–269.
   PubMed Web of Science ®Google Scholar
• Chiba H, Osanai M, Murata M, Kojima T, Sawada N 2008. Transmembrane proteins of tight junctions. Biochim Biophy Acta. 1778: 588–600.
   PubMed Web of Science ®Google Scholar
• Chow DK, Leong RW, Tsoi KK, Ng SS, Leung WK, Wu JC, et al 2009. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 104:647–654.
   PubMed Web of Science ®Google Scholar
• Clark MA, Hirst BH, Jepson MA 2000. Lectin-mediated mucosal delivery of drugs and microparticles. Adv Drug Deliv Rev. 43:207–223.
   PubMed Web of Science ®Google Scholar
• Collnot EM, Ali H, Lehr CM 2012. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 161:236.
   Web of Science ®Google Scholar
• Conrad K, Roggenbuck D, Laass MW 2014. Diagnosis and classification of ulcerative colitis. Autoimmunity Rev. 13:463–466.
   PubMed Web of Science ®Google Scholar
• Conradi RA, Hilgers AR, Ho NF, Burton PS 1991. The influence of peptide structure on transport across Caco-2 cells. Pharm Res. 8:1453–1460.
   PubMed Web of Science ®Google Scholar
• Cosnes J, Rousseau CG, Seksik P, Cortot A 2011. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 140:1785–1794.
   PubMed Web of Science ®Google Scholar
• Dai C, Wang B, Zhao H 2005. Microencapsulation peptide and protein drugs delivery system. Colloids Surf B Biointerfaces. 41:118.
   Web of Science ®Google Scholar
• Danese S, Sans M, Fiocchi C 2004. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev. 3:394–400.
   PubMed Web of Science ®Google Scholar
• Daugherty AL, Mrsny RJ 1999. Transcellular uptake mechanisms of the intestinal epithelial barrier part one. Pharm Sci Technolo Today. 2:145.
   Google Scholar
• Dave SH, Tilstra JS, Matsuoka K, Li F, Karrasch T, Uno JK, et al 2007. Amelioration of Chronic Murine Colitis by Peptide-Mediated Transduction of the IκB Kinase Inhibitor NEMO Binding Domain Peptide1. J Immunol. 179:7852–7859.
   PubMed Web of Science ®Google Scholar
• Deuring JJ, Haar C, Kuipers EJ, Peppelenbosch MP, Woude CJ 2013. The cell biology of the intestinal epithelium and its relation to inflammatory bowel disease. Int J Biochem Cell Biol. 45:800.
   Web of Science ®Google Scholar
• Di Marco M, Shamsuddin S, Razak KA, Aziz AA, Devaux C, Borghi E, et al 2010. Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation. Int J Nanomed. 5:37–49.
   PubMed Web of Science ®Google Scholar
• Donovan MD, Flynn GL, Amidon GL 1990. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res. 7:863–68.
   PubMed Web of Science ®Google Scholar
• Dorkoosh FA, Verhoef JC, Borchard G, Tehrani MR, Junginger HE 2001. Development and characterization of a novel peroral peptide drug delivery system. J Control Release. 71:308.
   Web of Science ®Google Scholar
• Eiamtrakarn S, Itoh Y, Kishimoto J, Yoshikawa Y, Shibata N, Murakami M, Takada K 2002. Gastrointestinal mucoadhesive patch system (GI-MAPS) for oral administration of G-CSF, a model protein. Biomaterials. 23:145–152.
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Peppercorn MA 2002. Ulcerative colitis. Lancet. 359: 331–340.
   PubMed Web of Science ®Google Scholar
• Fischer R, Mleczek MF, Hufnagel H, Brock R 2005. Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides. Chembiochem. 6:2126–2142.
   PubMed Web of Science ®Google Scholar
• FitzGerald AJ, Pu M, Marchbank T, Westley BR, May FEB, Boyle J, et al 2004. Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides. 25:793–801.
   PubMed Web of Science ®Google Scholar
• Fix JA 1996. Oral controlled release technology for peptides: status and future prospects. Pharm Res. 13:1760–1764.
   PubMed Web of Science ®Google Scholar
• Florence AT 2004. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target. 12:65–70.
   PubMed Web of Science ®Google Scholar
• Fonseca SB, Pereira MP, Kelley SO 2009. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev. 61:953–964.
   PubMed Web of Science ®Google Scholar
• Frey A, Neutra MR 1997. Targeting of mucosal vaccines to Peyer's patch M cells. Behring Inst Mitt. 98:376–389.
   PubMedGoogle Scholar
• Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S 1993. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol. 123:1777–1788.
   PubMed Web of Science ®Google Scholar
• Furuse M, Sasaki H, Fujimoto K, Tsukita S 1998. A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occluding in fibroblasts. J Cell Biol. 143:391–401.
   PubMed Web of Science ®Google Scholar
• Furuse M, Tsukita S 2006. Claudins in occluding junctions of humans and flies. Trends Cell Bio. 16:181–188.
   PubMed Web of Science ®Google Scholar
• Gangwar S, Pauletti GM, Wang B, Siahaan TJ, Stella VJ, Borchardt RT 1997. Prodrug strategies to enhance the intestinal absorption of peptides. Drug Discov Today. 2:148–154.
   Web of Science ®Google Scholar
• Gardner MLG 1987. Passage of intact peptides across the intestine. Adv Biosci. 65:99–106.
   Google Scholar
• Gearry RB, Richardson A, Frampton CM, Collett JA, Burt MJ, Chapman BA, Barclay ML 2006. High incidence of Crohn's disease in Canterbury, NewZealand: results of an epidemiologic study. Inflamm Bowel Dis. 12:936–943.
   PubMed Web of Science ®Google Scholar
• Giannasca PJ, Giannasca KT, Leichtner AM, Neutra MR 1999. Human intestinal M cells display the sialyl Lewis A antigen. Infect Immun. 67:946–953.
   PubMed Web of Science ®Google Scholar
• Gibson PR 1997. Ulcerative colitis: an epithelial disease? Bailliere's Clin Gastroenterol. 11:19.
   Web of Science ®Google Scholar
• Gitler C 1964. Protein digestion and absorption in nonruminants. In: Munro HN, Allison JB, Eds. Mammalian Protein Metabolism. New York: Academic Press, pp. 35–69.
   Google Scholar
• Goldberg M, Orellana IG 2003. Challenge for the oral delivery of macromolecules. Nat Rev Drug Dis. 2:289–295.
   PubMed Web of Science ®Google Scholar
• Gunisetty S, Tiwari SK, Bardia A, Phanibhushan M, Satti V, Habeeb MA, Khan AA 2012. The epidemiology and prevalence of Ulcerative colitis in the South of India. Open J Immunol. 2:144–148.
   Google Scholar
• Halfvarson J, Bresso F, D’Amato M, Jarnerot G, Pettersson S, Tysk C 2005. CARD15/NOD2 polymorphisms do not explain concordance of Crohn's disease in Swedish monozygotic twins. Dig Liver Dis. 37:768–772.
   PubMedGoogle Scholar
• Hanai H, Iida T, Ikeya K, Abe J, Maruyamab Y, Shimura T, et al 2013. A new paradigm in ulcerative colitis: Regulatory T cells are key factor which induces/exacerbates UC through an immune imbalance Molecular. Immunology, 54:173–180.
   Web of Science ®Google Scholar
• Harmar AJ 2004. Clinical endocrinology and metabolism. Receptors for gut peptides. Best Pract Res Clin Endocrinol Metab. 18:463.
   PubMed Web of Science ®Google Scholar
• Hering NA, Schulzke JD 2009. Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig Dis. 27:450–454.
   PubMed Web of Science ®Google Scholar
• Hong S, Yum S, Yoo HJ, Kang S, Yoon JH, Min D, et al 2012. Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis. Mol Pharm. 7:1310–1319.
   Web of Science ®Google Scholar
• Hong T, Jin GB, Yoshino G, Miura M, Maeda Y, Cho S, Cyong JC 2002. Protective effects of Polygalae root in experimental TNBS-induced colitis in mice. J Ethnopharmacol. 79:341.
   PubMed Web of Science ®Google Scholar
• Hussain N, Jaitley V, Florence AT 2001. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev. 50:107–142.
   PubMed Web of Science ®Google Scholar
• Hwang JW, Lee SJ, Kim YS, Kim EK, Ahn CB, Jeon YJ, et al 2012. Purification and characterization of a novel peptide with inhibitory effects on colitis induced mice by dextran sulfate sodium from enzymatic hydrolysates of Crassostrea gigas. Fish Shellfish Immunol. 33:993–999.
   PubMed Web of Science ®Google Scholar
• Ikesue K, Kopeckova P, Kopecek J 1993. Degradation of proteins by guinea pig intestinal enzymes. Int J Pharm. 95:171–179.
   Web of Science ®Google Scholar
• Jess T, Riis L, Jespersgaard C, Hougs L, Andersen PS, Orholm MK, et al 2005. Disease concordance, zygosity, and NOD2/CARD15 status: follow-up of a population-based cohort of Danish twins with inflammatory bowel disease. Am J Gastroenterol. 100: 2486–2492.
   PubMed Web of Science ®Google Scholar
• Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, et al 2002. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 13:481–489.
   Web of Science ®Google Scholar
• Jones GJR 2002. The potential use of receptor-mediated endocytosis for oral drug delivery. Adv Drug Deliv Rev. 20:83–97.
   Web of Science ®Google Scholar
• Kadiyala I, Loo Y, Roy K, Rice J, Leong KW 2010. Transport of chitosan-DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes. Eur J Pharm Sci. 39:103–109.
   PubMed Web of Science ®Google Scholar
• Kanwar B, Gao DW, Hwang AB, James P, Grenert JP, Williams SP, et al 2008. In vivo imaging of mucosal CD4 + T cells using single photon emission computed tomography in a murine model of colitis. J Immunol Methods. 329:21–22.
   PubMed Web of Science ®Google Scholar
• Kato E, Yamane S, Nomura R, Matsumoto K, Tashima K, Horie S, et al 2012. Dysfunction of neurogenic VIP-mediated relaxation in mouse distal colon with dextran sulfate sodium-induced colitis. Pharmacol Res. 65:204–212.
   PubMed Web of Science ®Google Scholar
• Kayhan GE, Gul M, Kayhan B, Gedik E, Ozgul U, Kurtoglu EL, et al 2013. Dexmedetomidine ameliorates TNBS-induced colitis by inducing immunomodulator effect. J Surg Res. 183:733–734.
   PubMed Web of Science ®Google Scholar
• Khafagy ES, Morishita M 2012. Oral biodrug delivery using cell- penetrating peptide. Adv Drug Deliv Rev. 64:531–539.
   PubMed Web of Science ®Google Scholar
• Kim CJ, Nolan JAK, Yang C, Archbold T, Fan MZ, Mine Y 2010. L-Tryptophan exhibits therapeutic function in a porcine model of dextran sodium sulfate (DSS)-induced colitis. J Nutrit Biochem. 212:468–475.
   Web of Science ®Google Scholar
• Kim CJ, Nolan JK, Yang C, Archbold T, Fan MZ, Mine Y 2009. L-cysteine supplementation attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. Biochim Biophys Acta. 1790:1161–1169.
   PubMed Web of Science ®Google Scholar
• Kim MS, Park SJ, Gu BK, Kim CH 2012. Ionically crosslinked alginate– carboxymethyl cellulose beads for the delivery of protein therapeutics. Appl Surf Sc.i, 262:28–33.
   Web of Science ®Google Scholar
• Kompella UB, Lee VHL 2001. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev. 46:211–245.
   PubMed Web of Science ®Google Scholar
• Kumar GP, Rajeshwarrao P 2011. Nonionic surfactant vesicular systems for effective drug delivery-an overview. Acta Pharm Sinica B. 1:208–219.
   Web of Science ®Google Scholar
• Kumar TR, Soppimath K, Nachaegari SK 2006. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol. 7:261–276.
   PubMed Web of Science ®Google Scholar
• Kwan KC 1997. Oral bioavailability and first-pass effects. Drug Metab Dispos. 25:1329–1336.
   PubMed Web of Science ®Google Scholar
• Langguth P, Bohner V, Heizmann J, Merkle HP, Wolffram S, Amidon GL, Yamashita S 1997. The challenge of proteolytic enzymes in intestinal peptide delivery. J Control Release. 46:39–57.
   Web of Science ®Google Scholar
• Lautenschlager C, Schmidt C, Fischer D, Stallmach A 2014. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev. 71:58–76.
   PubMed Web of Science ®Google Scholar
• Lee M, Nolan JK, Archbold T, Fan MZ, Juneja LR, Okubo T, Mine Y 2009. Therapeutic potential of hen egg white peptides for the treatment of intestinal inflammation. J Funct Foods. 1:161–169.
   Web of Science ®Google Scholar
• Lee YH, Fock K, See SJ, Ng TM, Khor C, Teo EK 2000. Racial differences in the prevalence of ulcerative colitis and Crohn's disease in Singapore. J Gastroenterol Hepatol. 15:622–625.
   PubMed Web of Science ®Google Scholar
• Li Y, Haar CD, Peppelenbosch MP, Van der Woude CJ 2012. SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer. Cytokine Growth Factor Rev. 23:128.
   Web of Science ®Google Scholar
• Li Z, Chen J, Sun W, Xu Y 2010. Investigation of archaeosomes as carriers for oral delivery of peptides. Biochem Biophys Res Commun. 394:412–417.
   PubMed Web of Science ®Google Scholar
• Limbergen JV, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al 2008. Definition of phenotypic characteristics of childhood- onset inflammatory bowel disease. Gastroenterology. 135:1114–1122.
   PubMed Web of Science ®Google Scholar
• Ling KL, Ooi CJ, Luman W, Cheong WK, Choen FS, Ng HS 2002. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. J Clin Gastroenterol. 356:144–148.
   Web of Science ®Google Scholar
• Lok KH, Hung HG, Ng CH, Kwong KC, Yip WM, Lau SF, et al 2008. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. J Gastroenterol Hepatol. 23:406–410.
   PubMed Web of Science ®Google Scholar
• MacAdam A 1993. The effect of gastro-intestinal mucus on drug absorption. Adv Drug Deliv Rev. 11:201–220.
   Web of Science ®Google Scholar
• Madara JL 1998. Regulation of the movement of solutes across tight junctions. Annu Rev Physiol. 60:143–159.
   PubMed Web of Science ®Google Scholar
• Mahato RI, Narang AS, Thoma L, Miller DD 2003. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 20:153–214.
   PubMed Web of Science ®Google Scholar
• Mankertz J, Schulzke JD 2007. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol. 23:379–383.
   PubMed Web of Science ®Google Scholar
• Maroni A, Curto MDD, Zema L, Foppoli A, Gazzaniga A 2013. Film coatings for oral colon delivery. Int J Pharm. 457:372–394.
   PubMed Web of Science ®Google Scholar
• McCrudden MT, Singh TR, Migalska K, Donnelly RF 2013. Strategies for enhanced peptide and protein delivery. Ther Deliv. 4:593–514.
   PubMedGoogle Scholar
• van der Merwe SM, Verhoef JC, Kotze AF, Junginger HE 2004. N-Trimethyl chitosan chloride as absorption enhancer in oral peptide drug delivery. Development and characterization of minitablet and granule formulations. Eur J Pharm Biopharm. 57:85–91.
   PubMed Web of Science ®Google Scholar
• Miller NS, Johnston TP 2005. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm. 294:201–216.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al 2012. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 142:46–54.
   PubMed Web of Science ®Google Scholar
• Morishita I, Morishita M, Takayama K, Machida Y, Nagai T 1992. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int J Pharm. 78:9–16.
   Web of Science ®Google Scholar
• Morishita M, Peppas NA 2006. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 11:905–910.
   PubMed Web of Science ®Google Scholar
• Morita N, Toki S, Hirohashi T, Minoda T, Ogawa K, Kono S, et al 1995. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J Gastroenterol. 30:1–4.
   PubMed Web of Science ®Google Scholar
• Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV Jr, Tysk C, et al 2013. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 62:630–649.
   PubMed Web of Science ®Google Scholar
• Nolan JK, Zhang H, Ibuki M, Nakamori T, Yoshiura K, Turner PV, et al 2012. The PepT1-transportable soy tripeptide VPY reduces intestinal inflammation. Biochim Biophys Acta. 1820:1753–1763.
   PubMed Web of Science ®Google Scholar
• Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ 2012. Ulcerative colitis. Lancet. 380:1606–1619.
   PubMed Web of Science ®Google Scholar
• Paganelli R, Levinsky RI 1980. Solid phase radioimmunoassay for detection of circulating food protein antigens in human serum. J Immunol Methods. 37:333–341.
   PubMed Web of Science ®Google Scholar
• Pandey RS, Sahu S, Sudheesh MS, Madan J, Kumar M, Dixit VK 2011. Carbohydrate modified ultrafine ceramic nanoparticles for allergen immunotherapy. Int Immunopharmacol. 11:925–931.
   PubMed Web of Science ®Google Scholar
• Pappenheimer JR, Reiss KZ 1987. Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J Membr Biol. 100:123–136.
   PubMed Web of Science ®Google Scholar
• Pardi DS, Kelly CP 2011. Microscopic colitis. Gastroenterology. 140:1155–1165.
   PubMed Web of Science ®Google Scholar
• Pauletti GM, Gangwar S, Knipp GT, Nerurkar MM, Okumu FW, Tamura K, et al 1996. Structural requirements for intestinal absorption of peptide drugs. J Control Release. 41:3–17.
   Web of Science ®Google Scholar
• Pauletti GM, Okumu FW, Borchardt RT 1997. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharm Res. 14:164–168.
   PubMed Web of Science ®Google Scholar
• Paulsen AF, Hoglund P, Lundin S, Paulsen O 1993. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf). 38:177–182.
   PubMed Web of Science ®Google Scholar
• Pearl DS, Shah K, Whittaker MA, Smith HN, Brown JF, Shute JK, Trebble TM 2013. Cytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity. J Crohn's Colitis. 7:481–489.
   Google Scholar
• Pettit DK, Gombotz WR 1998. The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals. Tibtech. 16:345–346.
   Web of Science ®Google Scholar
• Phelps CF 1978. Biosynthesis of mucus glycoprotein. Br Med Bull. 34:43–48.
   PubMed Web of Science ®Google Scholar
• Piekielna J, Perlikowska R, Gach K, Janecka A 2013. Cyclization in opioid peptides. Curr Drug Targets. 14:798.
   PubMed Web of Science ®Google Scholar
• Pinto JF 2010. Site-specific drug delivery systems within the gastro- intestinal tract: From the mouth to the colon. Int J Pharm. 395: 44–52.
   PubMed Web of Science ®Google Scholar
• Ponchel G, Touchard F, Duchene D, Peppas A 1987. Bioadhesive analysis of controlled release systems. I. Fracture and interpenetration analysis in poly(acrylic acid)-containing systems. J Control Release. 5:129–141.
   Google Scholar
• Qi K, Wu J, Wan J, Men X, Xu Z 2014. Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis. Peptides. 52:11–18.
   PubMed Web of Science ®Google Scholar
• Rabbi MF, Labis B, Metz-Boutigue MH, Bernstein CN, Ghia JE 2014. Catestatin decreases macrophage function in two mouse models of experimental colitis. Biochemical Pharmacology. 89: 386–398.
   PubMed Web of Science ®Google Scholar
• Raghvendra SR 2012. Nano-clays and drug delivery system: an overview. Int J Pharm World Rev. 3:1–16.
   Google Scholar
• Randall C, Vizuete J, Wendorf G, Ayyar B, Constantine G 2012. Current and emerging strategies in the management of Crohn's disease. Best Pract Res Clin Gastroenterol. 26:601–610.
   PubMed Web of Science ®Google Scholar
• Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, Savolainen T 2008. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 7:255–270.
   PubMed Web of Science ®Google Scholar
• Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F 2006. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine. 2:53–65.
   PubMed Web of Science ®Google Scholar
• Rekha MR, Sharma CP 2013. Oral delivery of therapeutic protein/ peptide for diabetes – Future perspectives. Int J Pharm. 440:48–62.
   PubMed Web of Science ®Google Scholar
• Renukuntla J, Vadlapudi AD, Patel A, Boddu SHS, Mitra AK 2013. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 447:76.
   Web of Science ®Google Scholar
• Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V 2006. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release. 116:1–27.
   PubMed Web of Science ®Google Scholar
• Rieux A, Pourcelle V, Cani PD, Brynaert JM, Preat V 2013. Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv Drug Deliv Rev. 65:833–844.
   PubMed Web of Science ®Google Scholar
• Roth B, Gustafsson R J, Jeppsson B, Manjer J, Ohlsson B 2014. Smoking- and alcohol habits in relation to the clinical picture of women with microscopic colitis compared to controls. BMC Women's Health. 14:8.
   PubMed Web of Science ®Google Scholar
• Rubas W, Cromwell ME, Shahrokh Z, Villagran J, Nguyen TN, Wellton M, et al 1996. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J Pharm Sci. 85:165–169.
   PubMed Web of Science ®Google Scholar
• Rundles CC 1987. Failure of antigen exclusion. In: Brostoff J, Challacombe SJ, Ed. Food Allergy and Intolerance, London: Tindall B, pp. 223–236.
   Google Scholar
• Saffran M, Kumar G, Savariar C, Burnham J, Williams F, Neckers D 1986. A new approach to the oral administration of insulin and other peptide drugs. Science. 233:1081–1084.
   PubMed Web of Science ®Google Scholar
• Sakuma S, Suzuki N, Kikuchi H, Hiwatari K, Arikawa K, Kishida A, Akashi M 1997. Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. Int J Pharm. 149:93–106.
   Web of Science ®Google Scholar
• Salmaso S, Caliceti P 2011. A useful tool to improve the biological performance of biotech drugs. In: Van der Walle C, Ed. Peptide and Protein Delivery. Boston: Elsevier Health Sciences, 247–290.
   Google Scholar
• Salmaso S, Caliceti P 2013. Self assembling nanocomposites for protein delivery: Supramolecular interactions of soluble polymers with protein drugs. Int J Pharm. 440:111–123.
   PubMed Web of Science ®Google Scholar
• Salmaso S, Caliceti P 2013. Self assembling nanocomposites for protein delivery: Supramolecular interactions of soluble polymers with protein drugs. Int J Pharm. 440:111.
   PubMed Web of Science ®Google Scholar
• Sant S, Tao SL, Fisher OZ, Xu Q, Peppas NA, Khademhosseini A 2012. Microfabrication technologies for oral drug delivery. Adv Drug Deliv Rev. 64:496–407.
   PubMed Web of Science ®Google Scholar
• Sato AK, Viswanathan M, Kent RB, Wood CR 2006. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol. 17:638–642.
   PubMed Web of Science ®Google Scholar
• Schnurch AB 2013. Nanocarrier systems for oral drug delivery: Do we really need them? Eur J Pharm Sci. 49:272–277.
   PubMed Web of Science ®Google Scholar
• Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, et al 2009. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci. 11:294–300.
   Web of Science ®Google Scholar
• Shakweh M, Ponchel G, Fattal E 2004. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv. 1:141–163.
   PubMedGoogle Scholar
• Shimizu M 2010. Interaction between food substances and the intestinal epithelium. Biosci Biotechnol Biochem. 74:232–241.
   PubMed Web of Science ®Google Scholar
• Singh D, Dubey P, Pradhan M, Singh MR 2013. Ceramic nanocarriers: versatile nanosystem for protein and peptide delivery. Expert Opin Drug Deliv. 10:241–259.
   PubMed Web of Science ®Google Scholar
• Sinha VR, Kumria R 2003. Microbially triggered drug delivery to the colon. Eur J Pharm Sci. 18:3–18.
   PubMed Web of Science ®Google Scholar
• Sizer PJH 1997. Towards an oral influenza vaccine. Trends Biotech. 15:282–285.
   PubMed Web of Science ®Google Scholar
• Sobczak M, Zakrzewski PK, Cygankiewicz AI, Mokrowiecka A, Chen C, Sałaga M, et al 2014. Anti-inflammatory action of a novel orally available peptide 317 in mouse models of inflammatory bowel diseases. Pharmacol Rep. 66:741–750.
   PubMed Web of Science ®Google Scholar
• Sood A, Midha V, Sood N, Bhatia AS, Avasthi G 2003. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 52: 1587–1590.
   PubMed Web of Science ®Google Scholar
• Stasikowska KO, Danilewicz M, Głowacka A, Wągrowska DM 2012. Mast cells and eosinophils are involved in activation of ulcerative colitis. Adv Medical Sci. 57:230–236.
   PubMed Web of Science ®Google Scholar
• Stoyanova II, Gulubova MV 2002. Mast cells and inflammatory mediators in chronic ulcerative colitis. Acta Histochem. 104:185.
   PubMed Web of Science ®Google Scholar
• Swaan PW 2002. Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pharm Res. 15:826–834.
   Web of Science ®Google Scholar
• Tan TM, Goh KL 2005. Ulcerative colitis in a multiracial Asian country: racial differences and clinical presentation among Malaysian patients. World J Gastroenterol. 11:5859–5862.
   PubMed Web of Science ®Google Scholar
• Tang VW, Goodenough DA 2003. Paracellular ion channel at the tight junction. Biophys J. 84:1660–1673.
   PubMed Web of Science ®Google Scholar
• Tomita M, Shiga M, Hayashi M, Awazu S 1998. Enhancement of colonic drug absorption by the paracellular permeation route. Pharm Res. 5:341–346.
   Google Scholar
• Travis SPL, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, et al 2008. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohn's Colitis. 2:24–62.
   Google Scholar
• Tsukita S, Furuse M, Itoh M 2001. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2:285–293.
   PubMed Web of Science ®Google Scholar
• Umashankar MS, Sachdeva RK, Gulati M 2010. Aquasomes: a promising carrier for peptides and protein delivery. Nanomedicine. 6:419–426.
   PubMed Web of Science ®Google Scholar
• Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N 2010. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater. 9:923–928.
   PubMed Web of Science ®Google Scholar
• Wood C, Miller J, Wilson G, Hidalgo IJ 1992. Effect of charge on affinity for the intestinal di-/tripeptide transporter. Pharm Res. 9:S–254.
   Google Scholar
• Woodley JF 1994. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst. 11:61–95.
   PubMed Web of Science ®Google Scholar
• Wootton R, Hazelwood R 1989. Relative affinity of a series of charged dipeptides for the peptide carrier of rabbit intestinal brush-border membranes. Biochem Soc Trans. 17:691–692.
   Web of Science ®Google Scholar
• Xing L, Dawei C, Liping X, Rongqing Z 2003. Oral colon-specific drug delivery for bee venom peptide: development of a coated calcium alginate gel beads-entrapped liposome. J Control Release. 93:293–300.
   PubMed Web of Science ®Google Scholar
• Xiong XY, Li QH, Li YP, Guo L, Li ZL, Gong YC 2013. Pluronic P85/poly(lactic acid) vesicles as novel carrier for oral insulin delivery. Colloids Surf B Biointerfaces. 111:282–288.
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Muranishi S 1997. Rectal drug delivery systems Improvement of rectal peptide absorption by absorption enhancers, protease inhibitors and chemical modification. Adv Drug Deliv Rev. 28:275–299.
   Web of Science ®Google Scholar
• Yang L, Sheldon BW, Webster TJ 2010. Nanophase ceramics for improved drug delivery: current opportunities and challenges. Am Ceramic Soc Bull. 89:24–33.
   Web of Science ®Google Scholar
• Yang M, Frokjaer S 2009. Novel formulation approaches for peptide and protein injectables. In: Jorgensen L, Nielsen H, Eds. Delivery Technologies for Biopharmaceuticals. Chichester: Wiley & Sons, pp. 9–28.
   Google Scholar
• Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, et al 2008. Epidemiology of inflammatory bowel disease in the Songpa- Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis. 14:542–549.
   PubMed Web of Science ®Google Scholar
• Yin B, Hu X, Wang J, Liang H, Li X, Niu N, et al 2011. Blocking TNF-α by combination of TNF-α- and TNFR-binding cyclic peptide ameliorates the severity of TNBS-induced colitis in rats. Eur J Pharmacol. 656:119–124.
   PubMed Web of Science ®Google Scholar
• Yun Y, Cho YW, Park K 2013. Nanoparticles for oral delivery: Targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev. 65:822–832.
   PubMed Web of Science ®Google Scholar
• Zhang X, Qi J, Lu Y, He W, Li X, Wu W 2014. Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomedicine. 10:167–176.
   PubMed Web of Science ®Google Scholar
• Zhang YZ, Li YY 2014. Inflammatory bowel disease: Pathogenesis. World J Gastroenterol. 20:91–99.
   PubMed Web of Science ®Google Scholar